Corbus Pharmaceuticals Holdings Inc (CRBP)

Over the past six months, Corbus Pharmaceuticals reported Q4 2025 financial results, including a net loss of approximately $20.6 million. The company completed a public offering that raised $75 million, extending its cash runway into 2028. Encouraging Phase 1/2 data for CRB-701 in HNSCC and cervical cancer were presented at ESMO 2025, and abstracts featuring updated clinical data for CRB-701 were accepted for presentation at ASCO 2026. The company plans to host a KOL event at ASCO 2026 and expects to initiate a registrational study for CRB-701 in second-line HNSCC in mid-2026, anticipating data for CRB-701 in combination with Keytruda in first-line HNSCC patients in Q4 2026. Encouraging data from a Phase 1a study of CRB-913 was reported, and the last patient first visit in the CANYON-1 Phase 1b study of CRB-913 for obesity was announced, with the study on track for completion in summer 2026. Guggenheim initiated coverage with a "Buy" rating. The share price increased by 78.14% from May 7, 2025, to May 6, 2026, reaching $10.92. The 52-week high was $20.56, and the 52-week low was $6.33.

As a clinical-stage pharmaceutical company, Corbus Pharmaceuticals Holdings, Inc. is primarily focused on the research, development, and clinical testing of its drug candidates. Its products are currently in various stages of clinical trials and are not yet commercialized; therefore, there is no information available regarding demand seasonality for Corbus Pharmaceuticals' products or services at this stage of its business operations.

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company focused on developing and commercializing innovative therapies, primarily in oncology and obesity. The company's pipeline includes CRB-701, a next-generation antibody-drug conjugate targeting Nectin-4 for head and neck squamous cell carcinoma and cervical cancer; CRB-601, an anti-integrin monoclonal antibody for solid tumors (program deprioritized); and CRB-913, a peripherally restricted CB1 receptor inverse agonist for obesity. The company also offers research and development services through collaborations.

Corbus Pharmaceuticals Holdings, Inc. is headquartered in Norwood, Massachusetts, United States. It has wholly-owned subsidiaries in Delaware, the United Kingdom, and Australia. The company aims to expand its presence in international markets through strategic partnerships and collaborations.

In the past year, Corbus Pharmaceuticals' brand reputation has been positively influenced by advancements in its clinical pipeline, including encouraging clinical data readouts for CRB-701 and CRB-913. The FDA granting Fast Track designations to CRB-701 for HNSCC and cervical cancer also reflects positively on the company's scientific efforts. Recent "Buy" initiations from analysts like Guggenheim suggest a favorable view from the investment community.

Corbus Pharmaceuticals Holdings, Inc. is owned by a mix of institutional and individual investors. Institutional shareholders hold 74.67% of the company, while insiders hold 83.21%. Major institutional owners include Cormorant Asset Management, LP, Orbimed Advisors Llc, Standard Life Aberdeen plc, Octagon Capital Advisors LP, Vanguard Group Inc, Citadel Advisors Llc, Prosight Management, LP, Armistice Capital, Llc, Stonepine Capital Management, LLC, and Renaissance Technologies Llc. Notable individual owners include Cormorant Asset Management LP, Sumner Burstein, Knoll Capital Management LP, and Mark Tepper.